WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;

(b) complements of any of the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;

(c) sequences having at least 90% identity to any one of the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and

(d) degenerate variants of any one of the sequences provided in SEQ ID NOs:10,486 – 10,536; SEQ ID NOs:10,537 – 10,580; SEQ ID NOs:10,581 – 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.

2 An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) sequences encoded by a polynucleotide of claim 1; and

(b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.

3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.

4. A host cell transformed or transfected with an expression vector according to claim 3.

5. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2.

6. A method for detecting the presence of a cancer in a patient, comprising the steps of:

(a) obtaining a biological sample from the patient;

(b) contacting the biological sample with a binding agent that binds to a polypeptide of claim 2;

(c) detecting in the sample an amount of polypeptide that binds to the binding agent; and

(d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.

7. A fusion protein comprising at least one polypeptide according to claim 2.

8. The fusion protein of claim 7, further comprising Ra12.

9. The fusion protein of claim 7, further comprising a His tag.

10. An oligonucleotide that hybridizes to the polynucleotides of claim 1.

11. A method for stimulating and/or expanding T cells specific for a tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:

(a) polypeptides according to claim 2;

(b) polynucleotides according to claim 1; and

(c) antigen-presenting cells that express a polypeptide according to claim 1, under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

12. An isolated T cell population, comprising T cells prepared according to the method of claim 11.

13. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second

component selected from the group consisting of:

(a) polypeptides according to claim 2;

(b) polynucleotides according to claim 1;

(c) antibodies according to claim 5;

(d) fusion proteins according to claim 7;

(e) T cell populations according to claim 12; and

(f) antigen presenting cells that express a polypeptide according to claim 2.

14. A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 13.

15. A method for the treatment of a cancer in a patient, comprising administering to the patient a composition of claim 13.

16. A method for determining the presence of a cancer in a patient, comprising the steps of:

(a) obtaining a biological sample from the patient;

(b) contacting the biological sample with an oligonucleotide according to claim 10;

(c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and

(d) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.

17. A diagnostic kit comprising at least one oligonucleotide according to claim 10.

18. A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group.

19. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

(a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least one component selected from the group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to

claim 1; and (iii) antigen presenting cells that express a polypeptide of claim 2, such that T cell proliferate;

(b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient.

20. An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) sequence provided in SEQ ID NO:10,469 or SEQ ID NO:10,470;

(b) complements of the sequence provided in SEQ ID NO:10,469 or SEQ ID NO:10,470;

(c) sequences having at least 90% identity to SEQ ID NO:10,469 or SEQ ID NO:10,470; and

(d) degenerate variants of SEQ ID NO:10,469 or SEQ ID NO:10,470.

21. An isolated polypeptide comprising an amino acid sequence provided in SEQ ID NO:10,471 or SEQ ID NO:10,474.

22. An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) sequence provided in SEQ ID NO:10,480;

(b) complements of the sequence provided in SEQ ID NO:10,480;

(c) sequences having at least 90% identity to a sequence of SEQ ID NO:10,480; and

(d) degenerate variants of a sequence provided in SEQ ID NO:10,480.

23. An isolated polypeptide comprising an amino acid sequence of SEQ ID NO:10,481.

24. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) sequences encoded by a polynucleotide of claim 20 or 22; and

(b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 20 or 22.

25. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) sequences provided in any one of SEQ ID NOs:10,599 – 10,819; and

(b) sequences provided in any one of SEQ ID NOs:10,820 – 10,842.

26. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) sequences provided in any one of SEQ ID NOs:10,849 – 10,908; and

(b) sequences provided in any one of SEQ ID NOs:10,909 – 10,968.